Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylat...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

PhilipL Jun. 27 at 1:47 PM

$RFL not selling a single share this cheap!!! Buy and hold!!!!

0 · Reply

PhilipL Jun. 26 at 7:43 PM

$RFL lets go team smack that ask so we can close 1.70+! Let’s go!!!!

0 · Reply

PhilipL Jun. 26 at 6:23 PM

$RFL maybe 2.00+ next week let’s go!!! Hold the line it’s time to shine!!!

0 · Reply

Markus_V Jun. 26 at 6:00 PM

$RFL Ready to go again to 2,XX in few days.

0 · Reply

Markus_V Jun. 26 at 5:55 PM

$RFL A punto de subir de nuevo a 2,XX....entre en 1,57 UPUPUP

0 · Reply

Markus_V Jun. 26 at 5:52 PM

$RFL

0 · Reply

sg44 Jun. 26 at 4:51 PM

$RFL go it's time to fill the gap from June 18 to 1.88.⬆️

0 · Reply

PhilipL Jun. 26 at 2:23 PM

$RFL still holding waiting patiently unlike some other penny flippers!

0 · Reply

Biotechnicity Jun. 26 at 6:30 AM

$RFL Last day to stay on track — Monday, June 30, 2025

1 · Reply

LC_Investor Jun. 26 at 3:14 AM

$RFL finally some peace here again & the one hit wonders have dissipated. A shout out to the true badger longs…who’s still here? Who still believes in taking this to market as the #1 NPC treatment & possibly Alzheimer’s down the road?

3 · Reply

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 22 days ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 5 weeks ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 7 weeks ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 2 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 2 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 3 months ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 3 months ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 4 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Dec 11, 2024, 7:00 AM EST - 7 months ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 8 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 9 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 11 months ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Aug 22, 2024, 6:50 AM EDT - 11 months ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 11 months ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 2 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 2 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 2:26 PM EST - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Jan 21, 2022, 7:00 AM EST - 3 years ago

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

Jan 18, 2022, 8:30 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 6, 2022, 8:30 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Dec 15, 2021, 4:30 PM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results

$Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition$

Dec 13, 2021, 8:00 AM EST - 3 years ago

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

PhilipL Jun. 27 at 1:47 PM

$RFL not selling a single share this cheap!!! Buy and hold!!!!

0 · Reply

PhilipL Jun. 26 at 7:43 PM

$RFL lets go team smack that ask so we can close 1.70+! Let’s go!!!!

0 · Reply

PhilipL Jun. 26 at 6:23 PM

$RFL maybe 2.00+ next week let’s go!!! Hold the line it’s time to shine!!!

0 · Reply

Markus_V Jun. 26 at 6:00 PM

$RFL Ready to go again to 2,XX in few days.

0 · Reply

Markus_V Jun. 26 at 5:55 PM

$RFL A punto de subir de nuevo a 2,XX....entre en 1,57 UPUPUP

0 · Reply

Markus_V Jun. 26 at 5:52 PM

$RFL

0 · Reply

sg44 Jun. 26 at 4:51 PM

$RFL go it's time to fill the gap from June 18 to 1.88.⬆️

0 · Reply

PhilipL Jun. 26 at 2:23 PM

$RFL still holding waiting patiently unlike some other penny flippers!

0 · Reply

Biotechnicity Jun. 26 at 6:30 AM

$RFL Last day to stay on track — Monday, June 30, 2025

1 · Reply

LC_Investor Jun. 26 at 3:14 AM

3 · Reply

PhilipL Jun. 24 at 5:57 PM

$RFL we were going for 1.70 and someone had to mess it up!!! 2.00+ let’s get this back to those lovely 2’s….

0 · Reply

CaseOfTheYips1 Jun. 24 at 2:48 PM

$RFL Feeling oddly comfortable with Jonas backing… maybe it’s just numb.. either way, we wait..

1 · Reply

PhilipL Jun. 24 at 12:46 PM

$RFL let’s continue our journey today… Insiders haven’t been loading for nothing!!! 2.00+ will be here before we know it..

1 · Reply

PhilipL Jun. 23 at 6:00 PM

$RFL

0 · Reply

Love_To_Learn Jun. 23 at 2:28 PM

$RFL metadata transfer off FMTO* shifting across the stocks! multiple bunch of them 1.52 super filler belonging to cyth active will now communicate with cyth moon indirectly $PLTR

1 · Reply

Love_To_Learn Jun. 23 at 2:26 PM

$IBO shifting tracks for u 3 $RFL $SLS

2 · Reply

Love_To_Learn Jun. 23 at 2:19 PM

$RFL using FMTOF for now !

0 · Reply

Love_To_Learn Jun. 23 at 10:56 AM

$RFL slight overlap with $KOPN due to market up n down there will be an issue that comes up on wednesday due to this so will make a subtle pivot slight breakup cause deviation and then change it after wednesday discussing short term only

1 · Reply

Love_To_Learn Jun. 23 at 10:50 AM

$PSTV remember previous messages rewarding the moon placement * will be merging them with $RFL moon situation when i made CYTH another stocks moon !

1 · Reply

sg44 Jun. 21 at 7:07 PM

$RFL imo to assert TransportNPC as the most comprehensive in clinical outcomes is to indirectly claim better efficacy compared to past phase 3 trials from competitors.

1 · Reply

sg44 Jun. 21 at 4:50 PM

$RFL is ranked 1st among all 11K companies in insider ownership 🥇

1 · Reply

History101 Jun. 20 at 6:34 PM

$RFL slowly getting back in...GLTALs!!

1 · Reply

Market Cap	57.90M
Revenue (ttm)	640,000.00
Net Income (ttm)	-34.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,376.56%
Debt to Equity Ratio	0.01

Volume	137,900
Avg Vol	262,344
Day's Range	N/A - N/A
Shares Out	35.09M
Stochastic %K	35%
Beta	0.91
Analysts	Strong Buy
Price Target	N/A